
Symbol Search

or enter GC* - Gold Futures

Quotes and Charts

YOU ARE HERE: Stocks » Quotes and Charts » News Headlines

Omeros Corp. (OMER)

4.94-0.44 (-8.18%) 4:00P EDT (NASDAQ)

Price Quote as of Thursday, May 23rd, 2013

Latest Omeros Corp. (OMER) Headlines

Omeros to Present at Two Upcoming Conferences

PR Newswire - Wed May 22, 6:00AM CDT

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the following two conferences: (full story)

Omeros Corporation concludes USD16.2m in registered direct offering

M2 - Wed May 15, 9:37AM CDT

Biopharmaceutical company Omeros Corporation (NasdaqGM:OMER) revealed on Tuesday the completion of its registered direct offering of 3,903,004 shares of its common stock. (full story)

Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock

PR Newswire - Tue May 14, 11:45AM CDT

Omeros Corporation (NASDAQ: OMER) today reported that it closed the registered direct offering of 3,903,004 shares of its common stock that was announced on May 9, 2013. The shares were sold at a price of $4.14 per share, which represented a two percent premium over the closing price on May 8, 2013. The shares were sold directly to affiliates of RA Capital Management and other investors without an underwriter or placement agent. Omeros received net proceeds from the offering of approximately $16.1 million, after deducting estimated offering expenses. (full story)

Omeros Corporation to close USD16.2m offering of common stock on or about 14 May 2013

M2 - Fri May 10, 12:53PM CDT

Biopharmaceutical company Omeros Corporation (NasdaqGM:OMER) said on Thursday that it will sell 3,903,004 shares of its common stock to RA Capital Management and other investors. (full story)

Omeros Corporation Reports First Quarter 2013 Financial Results

PR Newswire - Fri May 10, 6:00AM CDT

Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the first quarter of 2013. (full story)

Omeros Announces $16.2 Million Registered Direct Offering of Common Stock

PR Newswire - Thu May 09, 5:31PM CDT

Omeros Corporation (NASDAQ: OMER) today announced that it has agreed to sell 3,903,004 shares of its common stock at a price of $4.14 per share, a two percent premium over the closing price on May 8, 2013, for gross proceeds of $16.2 million. The shares were offered and are expected to be sold to RA Capital Management and other investors in a registered direct offering conducted without an underwriter or placement agent. The net proceeds from the offering, after deducting estimated offering expenses, will be approximately $16.1 million. The offering is expected to close on or about May 14, 2013. (full story)

MNOV, FOLD, KTOS, ACFN, INUV, OMER Expected To Be Down After Next Earnings Releases

M2 - Wed May 08, 7:00AM CDT

BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Thursday, May 9th 2013 and determining how the stocks have performed After their last 12 quarterly, 6 quarterly and December earnings reports. MediciNova Inc (NASDAQ:MNOV), Amicus Therapeutics Inc (NASDAQ:FOLD), Kratos Defense and Security Solutions Inc (NASDAQ:KTOS), Acorn Energy Inc (NASDAQ:ACFN), Inuvo Inc (AMEX:INUV), Omeros Corp (NASDAQ:OMER) are all expected to be Down After their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific (full story)

Omeros Requests Fast Track Designation for OMS824 for the Treatment of Huntington's Disease

PR Newswire - Wed May 01, 6:00AM CDT

Omeros Corporation (NASDAQ: OMER) today announced that it has requested Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the development of OMS824 for the treatment of Huntington's disease. OMS824 selectively inhibits phosphodiesterase 10 (PDE10), an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including Huntington's disease and schizophrenia. OMS824 has shown promising results in animal models directly relevant to Huntington's disease and, as previously announced, OMS824 was well tolerated and exhibited favorable pharmacokinetic properties in a Phase 1 clinical program. Omeros is currently advancing OMS824 into a Phase 2 program. (full story)

Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review

PR Newswire - Tue Apr 30, 6:00AM CDT

Omeros Corporation (NASDAQ: OMER) today announced that the European Medicines Agency (EMA) has confirmed that the Company's planned Marketing Authorization Application (MAA) for its ophthalmology product OMS302 can be submitted and reviewed under the EMA's centralized procedure. OMS302, which contains mydriatic (pupil-dilating) and anti-inflammatory agents, is the Company's product being developed for use during intraocular lens replacement, including cataract surgery and refractive lens exchange. EMA's Committee for Medicinal Products for Human Use granted this eligibility for OMS302 because it represents a significant therapeutic innovation. (full story)

Omeros Reports OMS302 Clinical Data Presented at the Annual ASCRS and ASOA Symposium and Congress

PR Newswire - Thu Apr 25, 6:00AM CDT

Omeros Corporation (NASDAQ: OMER) today reported analyses of Phase 2 and Phase 3 clinical data showing the favorable impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement (ILR). OMS302, which contains a mydriatic (pupil-dilating) agent and an anti-inflammatory agent, is the Company's product being developed for use during ILR, including cataract surgery and refractive lens exchange. These analyses were presented on April 21 at the Annual American Society of Cataract and Refractive Surgery (ASCRS) and American Society of Ophthalmic Administrators (ASOA) Symposium and Congress in San Francisco. (full story)